Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

The APOBEC-2 crystal structure and functional implications for the deaminase AID.

Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS.

Nature. 2007 Jan 25;445(7126):447-51.

PMID:
17187054
2.
3.

Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.

Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson S, Vartanian JP, Greeve J.

Hepatology. 2006 Jun;43(6):1364-74.

PMID:
16729314
4.

APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.

Stenglein MD, Harris RS.

J Biol Chem. 2006 Jun 23;281(25):16837-41.

5.

APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.

Chelico L, Pham P, Calabrese P, Goodman MF.

Nat Struct Mol Biol. 2006 May;13(5):392-9.

PMID:
16622407
6.

APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.

Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD.

Curr Biol. 2006 Mar 7;16(5):480-5.

7.

Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.

Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, Kodama Y, Endo Y, Yamauchi J, Matsumoto T, Takaori-Kondo A, Ikai I, Chiba T.

Biochem Biophys Res Commun. 2006 Mar 10;341(2):314-9.

PMID:
16426578
8.

Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Cullen BR.

J Virol. 2006 Feb;80(3):1067-76. Review. No abstract available.

10.

Restriction of foamy viruses by APOBEC cytidine deaminases.

Delebecque F, Suspène R, Calattini S, Casartelli N, Saïb A, Froment A, Wain-Hobson S, Gessain A, Vartanian JP, Schwartz O.

J Virol. 2006 Jan;80(2):605-14.

11.

APOBEC-mediated interference with hepadnavirus production.

Rösler C, Köck J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsäcker F.

Hepatology. 2005 Aug;42(2):301-9.

PMID:
16025511
12.

Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.

Suspène R, Guétard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8321-6.

13.

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC.

Nature. 2005 May 5;435(7038):108-14. Retraction in: Nature. 2010 Jul 8;466(7303):276.

PMID:
15829920
14.

Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.

Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K.

J Virol. 2005 May;79(9):5870-4.

15.
16.

G to A hypermutation of hepatitis B virus.

Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, Chayama K.

Hepatology. 2005 Mar;41(3):626-33.

PMID:
15726649
17.

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM.

Curr Biol. 2005 Jan 26;15(2):166-70.

18.

Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function.

Hu J, Flores D, Toft D, Wang X, Nguyen D.

J Virol. 2004 Dec;78(23):13122-31.

19.

Retroviral restriction by APOBEC proteins.

Harris RS, Liddament MT.

Nat Rev Immunol. 2004 Nov;4(11):868-77. Review.

PMID:
15516966
20.

APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.

Yu Q, Chen D, König R, Mariani R, Unutmaz D, Landau NR.

J Biol Chem. 2004 Dec 17;279(51):53379-86.

Items per page

Supplemental Content

Support Center